CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer Journal Article


Authors: Bange, E. M.; Han, N. A.; Wileyto, P.; Kim, J. Y.; Gouma, S.; Robinson, J.; Greenplate, A. R.; Hwee, M. A.; Porterfield, F.; Owoyemi, O.; Naik, K.; Zheng, C.; Galantino, M.; Weisman, A. R.; Ittner, C. A. G.; Kugler, E. M.; Baxter, A. E.; Oniyide, O.; Agyekum, R. S.; Dunn, T. G.; Jones, T. K.; Giannini, H. M.; Weirick, M. E.; McAllister, C. M.; Babady, N. E.; Kumar, A.; Widman, A. J.; DeWolf, S.; Boutemine, S. R.; Roberts, C.; Budzik, K. R.; Tollett, S.; Wright, C.; Perloff, T.; Sun, L.; Mathew, D.; Giles, J. R.; Oldridge, D. A.; Wu, J. E.; Alanio, C.; Adamski, S.; Garfall, A. L.; Vella, L. A.; Kerr, S. J.; Cohen, J. V.; Oyer, R. A.; Massa, R.; Maillard, I. P.; Maxwell, K. N.; Reilly, J. P.; Maslak, P. G.; Vonderheide, R. H.; Wolchok, J. D.; Hensley, S. E.; Wherry, E. J.; Meyer, N. J.; DeMichele, A. M.; Vardhana, S. A.; Mamtani, R.; Huang, A. C.
Article Title: CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer
Abstract: Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients with cancer who were hospitalized for COVID-19, patients with hematologic cancer had higher mortality relative to patients with solid cancer. In two additional cohorts, flow cytometric and serologic analyses demonstrated that patients with solid cancer and patients without cancer had a similar immune phenotype during acute COVID-19, whereas patients with hematologic cancer had impairment of B cells and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses. Despite the impaired humoral immunity and high mortality in patients with hematologic cancer who also have COVID-19, those with a greater number of CD8 T cells had improved survival, including those treated with anti-CD20 therapy. Furthermore, 77% of patients with hematologic cancer had detectable SARS-CoV-2-specific T cell responses. Thus, CD8 T cells might influence recovery from COVID-19 when humoral immunity is deficient. These observations suggest that CD8 T cell responses to vaccination might provide protection in patients with hematologic cancer even in the setting of limited humoral responses. © 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.
Journal Title: Nature Medicine
Volume: 27
Issue: 7
ISSN: 1078-8956
Publisher: Nature Publishing Group  
Date Published: 2021-07-01
Start Page: 1280
End Page: 1289
Language: English
DOI: 10.1038/s41591-021-01386-7
PUBMED: 34017137
PROVIDER: scopus
PMCID: PMC8291091
DOI/URL:
Notes: Article -- Export Date: 2 August 2021 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Ngolela Esther Babady
    114 Babady
  2. Jedd D Wolchok
    830 Wolchok
  3. Peter Maslak
    191 Maslak
  4. Anita Kumar
    103 Kumar
  5. Adam J Widman
    3 Widman
  6. Madeline Anne Hwee
    2 Hwee
  7. Susan E Dewolf
    5 Dewolf